Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep426 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Effects of bariatric surgery in patients with craniopharyngioma

Dischinger Ulrich , Kötzner Laura , Koschker Ann-Cathrin , Haas Christina , Herrmann Martin , Fassnacht Martin , Seyfried Florian

Effects of Bariatric Surgery in Patients with CraniopharyngiomaObjectives: The prime objective of this study is the identification of the limiting factors of metabolic surgeries on weight reduction in patients with craniopharyngioma (CP) and consecutive hypothalamic obesity (HO).Patients: As of now, 37 patients were included, of which5 patients presented with HO and earlier bariatric surgery (mean BMI 50.44 kg/m2), ...

ea0037oc1.3 | Adrenal 1 | ECE2015

[123/131I] azetidinylamide a novel radiotracer for diagnosis and treatment of adrenocortical tumours -- from bench to bedside

Hahner Stefanie , Heinze Britta , Herrmann Ken , Buck Andreas K , Blumel Christina , Hanscheid Heribert , Brumberg Joachim , Michelmann David , Nannen Lukas , Ries Martin , Fassnacht Martin , Allolio Bruno , Schirbel Andreas

Background: We have recently introduced [123/131I]iodometomidate (IMTO) which selectively binds to the adrenocortical enzymes aldosterone synthase and 11ß-hydroxylase as SPECT tracer. IMTO has been proven to be useful for molecular adrenal imaging and radiotherapy in adrenal cancer (ACC). As IMTO is rapidly inactivated by endogenous esterases which may impair target tissue to background activity and therapeutic efficacy, >50 new IMTO derivatives have been d...

ea0035eje1 | The European Journal of Endocrinology Prize Lecture | ECE2014

Adrenocortical carcinoma – current concepts and future perspectives

Fassnacht Martin

Adrenocortical carcinoma (ACC) is not only a rare and heterogeneous disease but also one of the most aggressive endocrine tumors. Despite significant advances in the last decade, its pathogenesis is still only incompletely understood and overall therapeutic means are unsatisfactory.During this lecture, we provide our personal view of the currently available treatment options and suggest the following research efforts that we consider timely and necessary...

ea0035eje1biog | The European Journal of Endocrinology Prize Lecture | ECE2014

European Journal of Endocrinology Prize Winner

Fassnacht Martin

The European Journal of Endocrinology Prize is awarded to a candidate who has contributed significantly to the advancement of the knowledge in the field of endocrinology through publication. Further information on the prize can be found at This year’s recipient is Prof. Martin Fassnacht. The prize will be presented as part of the ECE 2014 opening ceremony where ...

ea0022s24.2 | Diagnosis and treatment of endocrine malignancies | ECE2010

Diagnosis and treatment of adrenocortical carcinomas

Fassnacht Martin

Adrenocortical carcinoma (ACC) is a rare malignancy and most of the diagnostic and therapeutic strategies are not fully established according to criteria of evidence based medicine. However, pre-operatively a thorough endocrine work-up is strongly recommended ( In addition an adequate visualization of the tumor and potential metastases is mandatory for best patient care. Computerized tomography and magnetic reso...

ea0056gl1.1 | Guidelines: ESE - ENSAT guidelines on the management of adrenocortical carcinoma in adults | ECE2018

ESE - ENSAT guidelines on the management of adrenocortical carcinoma in adults

Fassnacht Martin

In our session we will present for the first time the results of our research and consensus process on the development of clinical practice guideline on adrenocortical carcinoma. A multidisciplinary team of 10 clinical and methodological experts reviewed the entire literature until 31.12.2017 and formulated recommendations on all aspects of the clinical management of adult patients with adrenocortical carcinoma....

ea0081p661 | Pituitary and Neuroendocrinology | ECE2022

Metyrapone vs osilodrostat in the short-term therapy of endogenous Cushing’s syndrome: results from a retrospective single center analysis

Detomas Mario , Altieri Barbara , Deutschbein Timo , Fassnacht Martin , Dischinger Ulrich

Background: Although surgery is considered the first-line treatment for patients with endogenous Cushing’s syndrome (CS), medical therapy is often required to control severe hypercortisolism. Metyrapone and osilodrostat are inhibitors of 11β-hydroxylase that have not been directly compared yet.Methods: Retrospective analysis of patients with adrenocorticotropin (ACTH)-dependent and ACTH-independent CS treated with metyrapone or osilodrostat (as...

ea0020s23.4 | Adrenocortical tumours – pathogenesis and management | ECE2009

Chemotherapy and radiotherapy for adrenocortical carcinoma (ACC)

Fassnacht Martin , Hahner Stefanie , Polat Buelent , Allolio Bruno

ACC is a rare, heterogeneous malignancy with poor prognosis. Data from the German ACC Registry (n=478) indicate a 5-year survival rate of 47%. In addition to mitotane, cytotoxic drugs are standard of care in advanced ACC. The best results have been reported by Berruti et al. for the combination of mitotane with etoposide, doxorubicin and cisplatin with an objective tumor response rate of 49% in 72 patients. A response rate of 36% was published for the combination...

ea0073aep826 | Late Breaking | ECE2021

The promising role of Agouti related peptide in the differentiation of ACTH-independent Cushing syndrome

Detomas Mario , Altieri Barbara , Fassnacht Martin , Dischinger Ulrich

BackgroundAgouti related peptide (AgRP) is a neuropeptide, produced by the hypothalamus and by the adrenal glands. AgRP is an antagonist of proopiomelanocortin (POMC) and its principal role is to stimulate appetite. Although current evidences suggest that AgRP levels are influenced by glucocorticoids, it is still not clear, whether they depend on adrenocorticotropic hormone (ACTH) or cortisol. One of the aims of this study was to address this issue. Furt...

ea0090oc9.4 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma

Altieri Barbara , Kimpel Otilia , Megerle Felix , Detomas Mario , Chifu Irina , Quinkler Marcus , Matthias Kroiss , Fassnacht Martin

Background: Mitotane is regularly used in patients with adrenocortical carcinoma (ACC) adjuvantly, in patients with high risk of recurrence, and in advanced disease. Multiple effects of mitotane result in adrenal insufficiency in virtually all patients. However, it is unclear how frequently the hypothalamic-pituitary-adrenal (HPA) axis is recovering after treatment discontinuation. Here, we aim to investigate the HPA axis after treatment with mitotane.Me...